Relative efficacy of oral analgesics after third molar extraction. Br Dent J 2004; 197:407-411 Data sources Dental trials were sought among systematic reviews of randomised, double-blind studies of analgesics in acute pain, which were identified from the Cochrane Library, Biological Abstracts, MEDLINE, PubMed and the Oxford Pain Relief database. Data extraction and synthesis Data were extracted independently by two reviewers. Dichotomous information from active and placebo treatments was used, first to calculate the statistical significance using relative risk, and then to evaluate the clinical relevance using number-needed-to-treat (NNT). Results Nonsteroidal anti-inflammatory drugs (NSAID) and cyclooxygenase (COX)-2 inhibitors had the lowest (best) NNT for the outcome of pain at least halved over 4-6 h compared with placebo. With the best performing analgesics, 50-70 patients out of 100 had good pain relief compared with about 10 out of 100 with placebo. Only paracetamol (600/650 mg) plus codeine (60 mg) was associated with any significant increase in any patient experiencing an adverse event.
Commentary
One of the questions most commonly asked by dentists is about the efficacy of analgesic treatments in dental pain. This paper is based on single-dose trials of oral analgesics after third molar extractions, thus providing information on the relative efficacy of certain doses, but not fixed regimens, of analgesics.
It is very interesting to note that the lowest (best) NNT were for nonselective COX inhibitors (termed NSAID in the paper) and selective COX-2 inhibitors (eg, the coxibs ) at standard or high doses. Examples to illustrate this point are valdecoxib 40 mg and diclofenac 100 mg (both NNT of 1.6), and rofecoxib 50 mg and diclofenac 50 mg (both NNT of 2.1); these were followed by ibuprofen 400 mg (NNT of 2.2). These results offer intriguing arguments for the debate over which factors (ie, potency of inhibition, selectivity of inhibition and/or pharmacokinetic properties) really cause the clinical effective analgesic effect of these drugs.
The results shown in the paper, however, may attract clinicians to make uncritical increases of the standard recommended doses of nonselective COX inhibitors without considering the possible relationship with increased incidence of adverse effects of these drugs. This is a real possibility: the negative adverse-effect profile of the coxibs on the cardiovascular system after long-term use has resulted in some of them being withdrawn from the market.
It is disappointing that the paper does not present more specific information on the incidence, following the use of COX inhibitors after third molar extractions, of alveolitis sicca dolorosa (dry socket) and other adverse effects of interest to dentists. Irrespective of their selectivity, differences between COX inhibitors in their adverseeffect profiles, especially regarding dry socket, would be of primary importance in a dentist's choice of analgesic treatment, at least after tooth extractions.
The present paper provides some reasonable and required answers to the question about efficacy of single-dose analgesics in dental pain. At least one small question remains unanswered after reading this paper, however. Why have the authors omitted paracetamol 1000 mg plus codeine 60 mg from their meta-analyses?
Dr RA Moore responds: The adverse events reported in these single-dose trials are those identified in our analysis of the studies available and this includes dry socket and others. The fact that adverse events are not better reported in the original studies is a topic on which we have published previously. 1, 2 The main point of these meta-analyses is to demonstrate how studies may be better performed in future, and we have a recent publication on this topic. 3 As the possible negative cardiovascular outcomes of coxibs postdate the submission of our review to the British Dental Journal in early 2003, it was difficult to include this in the discussion. Moreover, the current evidence is that cardiovascular effects of coxibs seen in cancer or precancer are also shared by aspirin, and that any increased cardiovascular risk in arthritis is shared with aspirin and NSAIDs. An electronic update of the Textbook of Pain (www.textbookofpain.com/) to be launched in August has an essay from us on the topic.
The question of paracetamol 1000 mg þ codeine 60 mg is a difficult one. We approached this in a systematic review looking at different sources of evidence a while ago. 4 The problem was that there were only two trials, with only 77 patients with dental surgery receiving this combination, and with unbalanced numbers that can skew statistics. We chose to omit it, having made a defence of the combination based on a wider body of evidence than just these two trials earlier.
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